Etiome
Preemptive medicines for disease intervention
CORE INFO
Etiome is a biotechnology company that develops preemptive medicines aimed at intervening at specific stages of disease progression, targeting chronic and progressive conditions like metabolic and neurodegenerative diseases.
- Etiome raised $50 million in a Series A funding round led by Flagship Pioneering in April 2025.nasdaq.com
- MedCity News highlighted Etiome's innovative approach to creating stage-specific therapies to intervene in disease progression before symptoms appear.medcitynews.com
WHY WE WOULD WORK AT ETIOME
Transform Healthcare
Join a mission to develop preemptive medicines that can halt or reverse chronic diseases, improving lives before conditions become debilitating.
Innovative Technology
Work with the cutting-edge Temporal Biodynamics™ platform, integrating machine learning and single-cell omics to redefine disease intervention.
Collaborative Team
Be part of a small, dedicated team of around 20 employees, fostering a culture of collaboration and innovation in a dynamic startup environment.
Competitive Funding
Benefit from strong financial backing with $50 million in Series A funding, ensuring resources for impactful research and development.
Pioneering Research
Contribute to groundbreaking studies, like the recent publication on early disease detection in *JAMIA Open*, positioning Etiome as a leader in biotechnology.
Meaningful Impact
Help create Biostaged Medicines that deliver therapies tailored to specific disease stages, revolutionizing patient care and outcomes.
MARKET AND TRACTION
TOTAL ADDRESSABLE MARKET
KEY METRICS
✦ KEY METRICCOMPETITIVE ADVANTAGE
MARKET POSITION
NOTABLE CUSTOMERS
PRODUCT AND TECH
Temporal Biodynamics™ Platform
Etiome's innovative Temporal Biodynamics™ platform integrates extensive population data, single-cell omics, and machine learning to accurately characterize disease stages. This technology is crucial for identifying stage-specific therapeutic targets and biomarkers, enabling the development of tailored therapies.
Biostaged Medicines
Biostaged Medicines are Etiome's unique therapies designed to be delivered to the right patient population at the right time, targeting specific stages of disease progression. This approach aims to halt or reverse chronic and progressive diseases before they become debilitating.
Single-Cell Omics
Single-cell omics is a key technology utilized by Etiome to analyze individual cells within a population, providing insights into molecular changes during disease progression. This detailed analysis is essential for developing precise interventions and understanding disease dynamics.
Machine Learning Integration
Etiome employs machine learning algorithms to analyze complex datasets and model disease progression, enhancing the accuracy of disease characterization. This integration allows for the identification of effective therapeutic targets and improves the overall efficacy of preemptive medicines.
Chronic Disease Focus
Etiome is dedicated to addressing chronic and progressive diseases, including metabolic, neurodegenerative, pre-cancerous, and autoimmune conditions. This focus underscores the company's mission to slow, prevent, or reverse the damage caused by these diseases through innovative therapeutic strategies.